Trevi Therapeutics to Attend September Investor and Medical Conferences

NEW HAVEN, Conn., Aug. 28, 2024 – Trevi Therapeutics, Inc. (Nasdaq: TRVI), a biopharmaceutical firm engaged in clinical development, announced that its senior management will participate in several investor and medical conferences throughout September. Trevi is focused on developing Haduvio™ (oral nalbuphine extended-release, ER) aimed at treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

The company’s itinerary is as follows:

2024 Wells Fargo Healthcare Conference
Location: Boston, MA
Dates: September 4-6, 2024
Representatives: Jennifer Good, President and CEO, and Lisa Delfini, CFO

European Respiratory Society (ERS) Congress 2024
Location: Vienna, Austria
Dates: September 7-11, 2024

H.C. Wainwright 26th Annual Global Investment Conference
Location: New York, NY
Dates: September 9-11, 2024
Corporate Presentation: September 10, from 12:30 p.m. to 1:00 p.m. ET
Representatives: Lisa Delfini, CFO and Farrell Simon, CCO
Note: This presentation is only available to conference attendees.

2024 Cantor Global Healthcare Conference
Location: New York, NY
Dates: September 17-19, 2024
Corporate Presentation: September 19, from 8:35 a.m. to 9:05 a.m. ET
Representative: Jennifer Good, President and CEO

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company involved in the development of Haduvio™ (oral nalbuphine ER), which targets chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio operates as a dual-action drug: a ĸ-opioid receptor agonist and a µ-opioid receptor antagonist. Its mechanism involves acting centrally in the brain and peripherally in the lungs, with the potential for a combined antitussive effect to manage chronic cough. It is important to note that parenteral nalbuphine is not classified under any schedule by the U.S. Drug Enforcement Agency.

Chronic cough significantly impacts patients' quality of life, affecting social, physical, and psychological well-being. In IPF patients, chronic cough can aggravate the disease, possibly leading to disease progression, death, or lung transplants. Presently, there are no approved treatments for chronic cough in IPF, and existing treatment options offer limited relief. Chronic cough affects up to 10% of adults, and Haduvio's expansion into treating RCC aims to reach patients with moderate to severe refractory chronic cough. Currently, the U.S. lacks approved treatments for RCC as well.

Trevi plans to market oral nalbuphine ER under the trade name Haduvio, though its safety and efficacy have yet to be assessed by regulatory authorities.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!